Robert W. Baird Issues Pessimistic Forecast for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its price objective decreased by Robert W. Baird from $112.00 to $90.00 in a research note released on Friday, MarketBeat reports. Robert W. Baird currently has an outperform rating on the medical device company’s stock.

A number of other research firms have also commented on DXCM. Mizuho lifted their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Morgan Stanley lifted their price objective on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 30th. Canaccord Genuity Group restated a “buy” rating and set a $106.00 target price on shares of DexCom in a research report on Friday, August 1st. Finally, The Goldman Sachs Group started coverage on DexCom in a research note on Friday, May 30th. They issued a “buy” rating and a $104.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.11.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $67.10 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom has a 1-year low of $57.52 and a 1-year high of $93.25. The stock has a market capitalization of $26.31 billion, a P/E ratio of 46.60, a P/E/G ratio of 1.41 and a beta of 1.48. The business has a 50-day moving average price of $78.27 and a two-hundred day moving average price of $78.13.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Equities analysts predict that DexCom will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. This trade represents a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock valued at $564,733 over the last ninety days. 0.32% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

Several large investors have recently made changes to their positions in DXCM. Vanguard Group Inc. lifted its position in DexCom by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after acquiring an additional 866,506 shares in the last quarter. Jennison Associates LLC raised its stake in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares during the period. Geode Capital Management LLC lifted its holdings in shares of DexCom by 3.4% in the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of DexCom during the first quarter worth about $554,893,000. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.